Devonian Health Group, Inc. (TSE:GSD) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Devonian Health Group Inc. reported a 749% increase in fourth-quarter revenue, reaching $9 million, driven by the successful launch of its generic drug DEXLANSOPRAZOLE in Canada. The company’s annual revenue also saw a significant rise of 660%, totalling $17.8 million, despite ending the year with a net loss per share.
For further insights into TSE:GSD stock, check out TipRanks’ Stock Analysis page.